Stock Track | Mesoblast Soars 5.12% Intraday on FDA BLA Filing Number for Rexlemestrocel-L Heart Failure Therapy

Stock Track

Jul 01

MESOBLAST LTD (MSB.AU) shares soared 5.12% during intraday trading on Wednesday, driven by a significant regulatory milestone for its lead therapy candidate.

The biotech company announced it received a Biologics License Application (BLA) filing number from the U.S. Food and Drug Administration for rexlemestrocel-L. The therapy is intended to prevent gastrointestinal bleeding due to right ventricular dysfunction in end-stage heart failure patients with a left ventricular assist device (LVAD).

Mesoblast also requested a modular review of the BLA, a process that can potentially expedite the regulatory pathway. The therapy holds both Orphan Drug Designation and Regenerative Medicine Advanced Therapy (RMAT) designation, which support eligibility for rolling or priority review by the FDA, highlighting the treatment's potential to address an unmet medical need.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/1174776615"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1174776615\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1174776615?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-01 11:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1174776615","market":"nz","top_or_hot":-1,"title":"Stock Track | Mesoblast Soars 5.12% Intraday on FDA BLA Filing Number for Rexlemestrocel-L Heart Failure Therapy","media":"Stock Track","content":"<p>MESOBLAST LTD (MSB.AU) shares soared 5.12% during intraday trading on Wednesday, driven by a significant regulatory milestone for its lead therapy candidate.</p><p>The biotech company announced it received a Biologics License Application (BLA) filing number from the U.S. Food and Drug Administration for rexlemestrocel-L. The therapy is intended to prevent gastrointestinal bleeding due to right ventricular dysfunction in end-stage heart failure patients with a left ventricular assist device (LVAD).</p><p>Mesoblast also requested a modular review of the BLA, a process that can potentially expedite the regulatory pathway. The therapy holds both Orphan Drug Designation and Regenerative Medicine Advanced Therapy (RMAT) designation, which support eligibility for rolling or priority review by the FDA, highlighting the treatment's potential to address an unmet medical need.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Mesoblast Soars 5.12% Intraday on FDA BLA Filing Number for Rexlemestrocel-L Heart Failure Therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Mesoblast Soars 5.12% Intraday on FDA BLA Filing Number for Rexlemestrocel-L Heart Failure Therapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-07-01 11:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>MESOBLAST LTD (MSB.AU) shares soared 5.12% during intraday trading on Wednesday, driven by a significant regulatory milestone for its lead therapy candidate.</p><p>The biotech company announced it received a Biologics License Application (BLA) filing number from the U.S. Food and Drug Administration for rexlemestrocel-L. The therapy is intended to prevent gastrointestinal bleeding due to right ventricular dysfunction in end-stage heart failure patients with a left ventricular assist device (LVAD).</p><p>Mesoblast also requested a modular review of the BLA, a process that can potentially expedite the regulatory pathway. The therapy holds both Orphan Drug Designation and Regenerative Medicine Advanced Therapy (RMAT) designation, which support eligibility for rolling or priority review by the FDA, highlighting the treatment's potential to address an unmet medical need.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MSB.AU","symbol_name":"MESOBLAST LTD","start_time":0,"source_url":"","article_id":"1174776615","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1174776615","pubTimestamp":1782877717,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"MESOBLAST LTD (MSB.AU) shares soared 5.12% during intraday trading on Wednesday, driven by a significant regulatory milestone for its lead therapy candidate.The biotech company announced it received...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MSB.AU":"MESOBLAST LTD"},"translate_title":"股票追踪|Mesoblast盘中大涨5.12%Rexlemestrocel-L心衰疗法FDA BLA备案号","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MSB.AU":1},"content_text":"MESOBLAST LTD (MSB.AU) shares soared 5.12% during intraday trading on Wednesday, driven by a significant regulatory milestone for its lead therapy candidate.The biotech company announced it received a Biologics License Application (BLA) filing number from the U.S. Food and Drug Administration for rexlemestrocel-L. The therapy is intended to prevent gastrointestinal bleeding due to right ventricular dysfunction in end-stage heart failure patients with a left ventricular assist device (LVAD).Mesoblast also requested a modular review of the BLA, a process that can potentially expedite the regulatory pathway. The therapy holds both Orphan Drug Designation and Regenerative Medicine Advanced Therapy (RMAT) designation, which support eligibility for rolling or priority review by the FDA, highlighting the treatment's potential to address an unmet medical need.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}